Cytovant

About Cytovant

Cytovant Sciences is a clinical-stage biopharmaceutical company established to develop and commercialize cellular therapeutics specifically for Asian patient populations. Launched in April 2019 by Roivant Sciences and its Chinese subsidiary Sinovant Sciences, the company operates with a strategic focus on diseases prevalent in Asia. John Xu, who holds a PhD in biochemistry and molecular biology from Harvard University and has prior experience at GSK China and Mab-Legend Biotech, was appointed as President to lead the company.

The company's business model centers on in-licensing and co-developing promising cell therapies for the Asian market, which includes Greater China, South Korea, and Japan. A cornerstone of its strategy was a multi-program partnership with Medigene AG, a German biotechnology company. This collaboration granted Cytovant exclusive rights to develop and commercialize a portfolio of immunotherapies, including a T-cell receptor (TCR) therapy targeting the NY-ESO-1 tumor antigen and a dendritic cell (DC) vaccine. The agreement involved an upfront payment of $10 million to Medigene, with potential milestone payments exceeding $1 billion, plus royalties on net sales. Cytovant also secured $23.5 million in a 2020 financing round from investors including BNH Investment and POSCO Capital to advance its clinical programs.

Cytovant's therapeutic focus is on T-cell receptor (TCR-T) and dendritic cell (DC) vaccine technologies. The company aims to address the specific immunological characteristics and disease burdens of Asian populations, a niche it believes is not adequately served by existing therapies. Its lead programs included CVT-TCR-01, a TCR-T therapy for solid tumors, and CVT-DC-01, a DC vaccine for acute myeloid leukemia (AML). These therapies work by engineering a patient's own T-cells to recognize and destroy cancer cells. The business was structured to handle the entire lifecycle from development and manufacturing to commercialization, leveraging Medigene's discovery platform while retaining sole responsibility for bringing the therapies to market in its licensed territories. However, reports from mid-2022 indicate the company's website became inactive after the development of its main product was discontinued, suggesting a halt in operations.